Navigation Links
Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
Date:10/28/2008

Boston Healthcare grows to meet increasing global demand for health

economics and market access support

BOSTON, Oct. 28 /PRNewswire/ -- Boston Healthcare Associates, Inc. today announced the appointment of Adam Barak as Vice President.

Mr. Barak brings 16 years of pricing and reimbursement experience, including the development of global pricing and reimbursement strategies for drugs, medical devices, and diagnostics in a wide range of therapeutic areas including oncology, pulmonary medicine, gastroenterology, cardiovascular medicine, neurology, and critical care.

"Adam's appointment demonstrates Boston Healthcare's continued commitment to expanding the scope and reach of our services," said Joseph Ferrara, President of Boston Healthcare. "His wealth of experience in pricing and reimbursement will strengthen our position internationally, and provide the expertise and leadership we need to serve our clients more effectively worldwide. Adam is a strong addition to the executive management team and an asset to our global strategy."

Mr. Barak joined GlaxoWellcome's International Pricing & Reimbursement division in 1996. In 1997, Mr. Barak became Head of European Pricing, managing the regional function and developing international pricing strategies for four of the seven GlaxoWellcome therapy areas, including European pricing strategies for CNS, cardiovascular, oncology, anesthesiology and diabetes drugs. In 2001, Mr. Barak joined Oxford GlycoSciences as International Pricing and Reimbursement Manager, developing global pricing, reimbursement, and market access strategy for Zavesca, the company's first pharmaceutical launch. In 2002, Mr. Barak established his own consultancy, ABPPC Ltd, and formed a global network of consultants that provide the international pharmaceutical and health care community with specialized support for pricing, reimbursement, and market access. The network covers 22 countries, and is represented by Boston Healthcare in the UK and US.

About Boston Healthcare

Boston Healthcare assists emerging and established biopharmaceutical, medical device and diagnostic companies in gaining a competitive advantage in the health care marketplace by helping them unlock the value of innovative drugs, devices, and diagnostics. These companies rely on Boston Healthcare to create opportunities, navigate complexity, grow their businesses, and achieve objectives through reimbursement, business development, and market strategies. Clients draw on Boston Healthcare's unique approach to gain a real-world edge in a highly competitive health care environment.

Contact:

Michal Taton

Boston Healthcare

(617) 912-5119

mtaton@bostonhealthcare.com


'/>"/>
SOURCE Boston Healthcare Associates, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
2. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
3. Boston Scientific Provides Update on Involuntary Selling of Its Stock by Co-Founders
4. Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent
5. Boston Scientific Announces FDA Approval of TAXUS(R) Express2(TM) Atom(TM) Stent System, First Drug-Eluting Stent For Small Vessels
6. Boston Scientific to Participate in UBS Global Life Sciences Conference
7. Boston Scientific Announces Court Decision
8. IBC Life Sciences Kicks Off the 13th Annual Drug Discovery & Development of Innovative Therapeutics World Congress in Boston, Massachusetts
9. InNexus Biotechnology CEO and Chief Scientific Officer to Present at IBCs Annual World Congress Conference in Boston on Aug 6th
10. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
11. TechCFO Adds Gary Strickland as Partner in Boston Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... AMSTERDAM , April 20, 2017 Dutch philosopher Koert ... of ,Next Nature, at the University of Technology in Eindhoven - has ... In this letter, he calls on humanity to avoid becoming a slave and ... race. ... Dutch philosopher Koert van Mensvoort – founder of ...
(Date:4/20/2017)... -- For today, Stock-Callers.com redirects investors, attention to ... clinical research aimed at treating diseases and medical conditions. Under ... Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), and ZIOPHARM ... our complimentary research reports on these stocks now at: ... http://stock-callers.com/registration ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have recently emerged ... of the Protein and Cell Analysis Education Webinar Series , will focus on ... in current and future applications. , Many flow cytometers have unique capabilities and ...
(Date:4/19/2017)... ... April 18, 2017 , ... Optofluidics today announced that ... after the company changed focus to making analytical tools for biopharmaceutical quality control. ... technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert Hart and David Erickson ...
Breaking Biology Technology:
(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):